Reactivation of human herpesvirus-6 (HHV-6) frequently occurs following hematopoietic SCT (HSCT), and has been associated with clinical consequences in many patient populations. HHV-6 reactivation and HHV-6 encephalitis seem to occur more frequently in patients undergoing HSCT with cord blood (CB) as the stem cell source. We have conducted a systematic literature review and meta-analysis to investigate the clinical significance of this correlation. A systematic review of publications indexed in PubMed was performed for HSCT studies published over the past 10 years that fit inclusion criteria. Data on prevalences of HHV-6 reactivation and HHV-6 encephalitis post HSCT were abstracted from 19 papers. Meta-analyses were conducted to calculate combined prevalence estimates. The prevalences of HHV-6 reactivation and encephalitis were compared among CB vs non-CB HSCT. Prevalences of HHV-6 reactivation and HHV-6 encephalitis were significantly higher in patients receiving CB as the stem cell source than in patients receiving another stem cell source (72.0% vs 37.4%, Po0.0001; 8.3% vs 0.50%, Po0.0001, respectively). HHV-6 reactivation and HHV-6 encephalitis are significant complications in the post-HSCT setting, particularly in patients receiving CB as the stem cell source. Thus, patients undergoing umbilical CB transplantation should be closely monitored for HHV-6 reactivation.
INTRODUCTION
Following the first successful umbilical cord blood transplant (CBT) procedure in 1989, 1 umbilical cord blood (CB) has become increasingly accepted as a viable alternative source of hematopoietic stem cells for use in allo-SCT. CBT is now routinely utilized for the treatment of both adult [2] [3] [4] [5] and pediatric 6 patients with hematological diseases, with similar reported outcomes as compared with hematopoietic SCT (HSCT) in which either adult BM or peripheral blood was used as a source of stem cells (non-CB HSCT). [7] [8] [9] Many human herpesviruses (HHVs) can be reactivated following HSCT, and have been associated with adverse outcomes in this clinical setting. In particular, a distinct increase in HHV-6 reactivation and encephalitis following CBT (compared with HSCT with other stem cell sources) has emerged in the recent literature. 10, 11 HHV-6 is the collective name for HHV-6A and HHV-6B, 12, 13 two closely related beta-herpesviruses that establish primary infection in early childhood and maintain lifelong persistent infection with a combined seroprevalence of 490% in adults. [14] [15] [16] [17] Of the two, HHV-6B is the variant implicated in nearly all documented cases of HHV-6 reactivation following HSCT, which typically occurs within 30 days of HSCT. 18 One of the most severe consequences of HHV-6 reactivation among post-transplant patients is infection of the central nervous system (CNS), which can lead to the development of HHV-6 encephalitis. [19] [20] [21] HHV-6 encephalitis can result in serious neurological sequelae, such as biphasic seizures and other symptoms of post-transplant acute limbic encephalitis. [22] [23] [24] [25] Symptoms often include confusion, seizures, delirium, aphasia, amnesia, emotional outbursts, hypersexuality, hemiparesis, hemiplegia, ataxia, hyperreflexia, syndrome of inappropriate diuretic hormone secretion and electroencephalography abnormalities. 22 ,23 HHV-6 encephalitis is also associated with a high rate of long-term sequelae and mortality. In a review of post-transplant acute limbic encephalitis associated with HHV-6, Seeley et al. 23 found that 5 out of 9 (56%) HHV-6 þ post-transplant acute limbic encephalitis patients died, while 3 out of 4 (75%) of the surviving patients maintained persistent cognitive impairment. In another survey of eight Japanese patients with HHV-6 encephalitis, three died and four out of five patients who survived suffered from permanent neurological disability. 22 A recent study from Harvard reports that death due to HHV-6 post-transplant acute limbic encephalitis occurred in 50% of all affected patients who received CB as the stem cell source (5/10), and in none (0/9) who received adult-donor stem cells. 25 In addition to encephalitis, HHV-6 reactivation has been associated with an increased risk of GVHD, delayed engraftment, cytopenia, opportunistic infections and fever. 19, [26] [27] [28] [29] [30] [31] There is still a considerable uncertainty on the clinical significance of HHV-6 reactivation, and routine testing for HHV-6 is not currently performed at most transplant centers. The purpose of our study was to conduct a systematic review of the literature and a meta-analysis to clarify the relationship between CBT and HHV-6 reactivation and assess the pooled prevalence of encephalitis among CBT patients.
MATERIALS AND METHODS

Literature search strategy
A systematic review of publications indexed in the PubMed database was performed for HSCT studies published in the past 10 years (1 January 2002-27 February 2012) according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines. 32 Independent searches for six key phrases ('cell transplant', 'cell transplantation', 'stem cell', 'cord blood', 'allogeneic' and 'hematopoietic') were paired independently with 'HHV-6', 'HHV6' and 'Herpesvirus-6' (18 total independent searches).
Study selection
Case reports, papers without original clinical data on SCT and papers not published in the English language were first excluded. Of the remaining publications, only studies with (i) a study cohort of at least 15 HSCT patients with at least 1 being CB, (ii) a minimum of monthly surveillance for HHV-6 reactivation as an initial study parameter and (iii) independent data available for patients who received CB as the stem cell source vs non-CBT recipients were included in this review.
Two reviewers (JCP and NRZ) independently selected studies by examining titles and abstracts to determine those potentially relevant to our study question. Reported results of these identified studies were further analyzed for inclusion, and any differences were resolved by consensus (JCP and NRZ). A PRISMA flow diagram to illustrate the entire systematic literature review and selection process has been provided in Figure 1 .
Data extraction
Publications that met the inclusion criteria were subjected to duplicate data extraction by two reviewers (JCP and NRZ) for the following parameters, and arranged into tables:
Prevalence of HHV-6 reactivation in patients receiving CB as the stem cell source compared with patients receiving stem cell sources other than CB (Table 1) . Prevalence of HHV-6 encephalitis (when defined as PCR detection of HHV-6 DNA in the cerebrospinal fluid (CSF) and CNS dysfunction) in patients receiving CB as the stem cell source compared with patients receiving stem cell sources other than CB (Table 2) .
Specifically, information extracted from each study included: the numbers of CBT and non-CBT patients, how HHV-6 reactivation was defined, whether the patients were adults or children, the case definition used for HHV-6 encephalitis and the numbers of patients who developed post-transplantation HHV-6 reactivation or HHV-6 encephalitis. We decided to define HHV-6 encephalitis more stringently than some of the authors in our analysis and excluded studies that did not confirm HHV-6 encephalitis by PCR DNA testing of CSF in all patients. Most studies did not provide information to enable to exclude chromosomally integrated HHV-6 (ciHHV-6).
Study quality assessment
This systematic review and meta-analysis was performed according to the PRISMA guidelines. Identified through independent searches of the PubMed online literature database for six key phrases ("cell transplant" , "cell transplantation" , "stem cell" , "cord blood" , "allogeneic" , and "hematopoietic") paired independently with "HHV-6" , "HHV6" , and "Herpesvirus-6" (18 total independent searches). Included in meta-analysis: "Prevalence of HHV-6 Reactivation" (table 1) Although these two articles fit the initial inclusion criteria, only qualitative data was provided for their cohorts, so no quantitative analysis could be contributed for inclusion in our analysis.
Although these two articles included data for the prevalence of HHV-6 encephalitis, they did not confirm this diagnosis by HHV-6 DNA detection in CSF, and were thus excluded from the final meta-analysis (Ogata 2008 , Ogata 2010 ).
One article included data for both HHV-6 reactivation and HHV-6 encephalitis (Ishiyama 2011). Data from this article has been included in the meta-analysis for HHV-6 reactivation, but not for HHV-6 encephalitis, as the authors did not confirm diagnosis by CSF positivity. Another article (Mori 2010 ) included only partial data for HHV-6 encephalitis that was confirmed by CSF positivity. This partial data has been included in the meta-analysis for HHV-6 encephalitis. HHV-6 encephalitis in umbilical cord blood transplantation ME Scheurer et al
Statistical analysis
The prevalences of HHV-6 reactivation and HHV-6 encephalitis were calculated for each study, separately for CBT and non-CBT recipients.
Meta-analyses were conducted to calculate combined estimates for these prevalences, using random effects models with inverse-variance weights. Forest plots were built using STATA's user-developed 'metan' procedure. 
Adult
The occurrence of unexplained neuropsychological disorders associated with a positive quantitative PCR for HHV-6 in the CSF.
9.3% (4/43) 2.5% (4/154) Mori et al.
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Mixed
The occurrence of encephalitis with HHV-6 DNA detected in the CSF a . For patients unable to undergo lumbar puncture, HHV-6-associated encephalitis/myelitis was diagnosed if they satisfied more than two of the following three criterion: (1) typical clinical manifestations; (2) detection of HHV-6 viral DNA in PB; or (3) limbic encephalopathy based on the selective involvement of the medial temporal lobe on MRI.
11.8% (6/51) 
Pediatric
The presence of neurological manifestation, namely change of conscious level, including lethargy, irritability, change of personality or behavior that persisted for more than 24 h in conjunction with detection of HHV-6 DNA in CSF samples by PCR and in the absence of any other identifiable etiology. Although Mori et al. initially reported 13 cases of HHV-6 encephalitis, only 9 of these were diagnosed by detection of HHV-6 in the CSF by PCR. For the purposes of this analysis, we excluded cases of limbic encephalitis that were diagnosed with only abnormalities in the limbic area on imaging and positive plasma PCR.
b After 2/16 unrelated HCT cases resulted in HHV-6 encephalitis, a clinical policy of antiviral prophylaxis during conditioning (IV ganciclovir 5 mg/kg twice daily from day À 7 through day À 1) was implemented for all cases of unrelated HCT. This resulted in a decreased prevalence of HHV-6 encephalitis (2/38) for the remaining cases of unrelated HCT. All the four cases of HHV-6 encephalitis in this study were observed following unrelated cord blood transplant. c Combined prevalence estimate from random effects meta-analysis. d P-value from Chi-squared test of pooled prevalence between umbilical cord blood transplant (CBT) and non-CBT groups.
HHV-6 encephalitis in umbilical cord blood transplantation ME Scheurer et al
Chi-squared tests were performed on the combined prevalence estimates for both HHV-6 reactivation (Table 1 ) and HHV-6 encephalitis (Table 2) to determine whether there were statistically significant differences between the CBT vs non-CBT groups. Because there were so few published studies examining the outcomes of interest, meta-analyses were not stratified by adult, pediatric or mixed age cases. However, the use of random effects models should account for some of the between-study variation related to age and other demographic differences between study populations. All statistical analyses were conducted in STATA version 12.
RESULTS
The systematic literature review yielded a total of 19 publications, and all data extracted from the identified studies were identical between the two reviewers ( Figure 1) . Data from thirteen studies were used for the meta-analysis on the prevalence of HHV-6 reactivation ( Table 1 ). In one case, a discrepancy in the reporting of data was clarified through direct contact with the corresponding author. 34 The combined prevalence estimates of HHV-6 reactivation, as defined by individual study criteria, were 72.0% among CBT recipients and 37.4% among non-CBT recipients (Po0.0001). Both combined prevalence estimates were significantly different from zero (Po0.0001). The forest plots provide a visualization of the prevalences and 95% confidence intervals for each study (Figures 2a and b) . The study-specific proportions of non-CBT recipients who experienced HHV-6 reactivation range 0-0.7 (0-70%) (Figure 2b ).
Seven studies contributed to the meta-analysis on the prevalence of HHV-6 encephalitis among CBT recipients (Table 2) . Six studies were used to calculate the combined prevalence in non-CBT recipients. The combined prevalence estimate for HHV-6 encephalitis, as confirmed by a positive CSF PCR test, among patients who underwent CBT was 8.3%, whereas the combined estimate among patients who received non-CB HSCT was 0.5%. A Chi-squared test indicated that the prevalence of HHV-6 encephalitis in patients receiving CB as the stem cell source was significantly greater than in patients receiving non-CB HSCT (Po0.0001). Both combined prevalence estimates were significantly different from zero (Po0.0001 for estimate among CBT recipients; P ¼ 0.04 among non-CBT recipients).
Twenty-one reported cases of HHV-6 encephalitis from six studies included at least partial peripheral blood-analysis data in addition to CSF surveillance for HHV-6 (not shown). Of these, 18 out of 21 were associated with HHV-6 reactivation in the peripheral blood (HHV-6 DNA positive via PCR analysis on serum or plasma). The remaining three cases were negative for HHV-6 DNA by serum PCR analysis.
DISCUSSION
This systematic review supports the conclusion that the use of CB grafts for HSCT is associated with a significantly increased prevalence of both HHV-6 reactivation and HHV-6 encephalitis in the post-HSCT setting. Some publications have suggested that the increased prevalence of HHV-6 reactivation may be due to the large number of immature ('antigen-naive') T cells present in umbilical CB, which inherently lacks the mature ('antigenexperienced' or 'memory') T cells necessary for immune reconstitution following HSCT. [35] [36] [37] In addition, because the newborn is generally naive for HHV-6 infection, CB lacks HHV-6-specific T cells, which could help in the containment of HHV-6 replication following engraftment. In fact, CB-derived T lymphocytes are often utilized to facilitate the active replication of HHV-6 in vitro. [38] [39] [40] HHV-6 is the only known herpesvirus that utilizes CD46 for infection and entry into the host cell. [41] [42] [43] [44] Interestingly, a higher expression of CD46 is observed on the surface of untreated CB cells compared with G-CSF-mobilized hematopoietic progenitor cells used in HSCT, which may contribute to the increased prevalence of post-CBT HHV-6 reactivation. 10, 45, 46 However, several lines of evidence suggest that other cellular factors in addition to CD46 are crucial to the establishment of active HHV-6 infection in vivo. 41 Ogata et al. 47 demonstrated that serum IL-6 levels increase dramatically in patients experiencing HHV-6 reactivation, showing a correlation between high levels of IL-6 in serum and CSF and the development of encephalitis. Several other studies have also suggested a significant role for IL-6 in the development of encephalitis through various proposed mechanisms. [48] [49] [50] The higher rate of HHV-6 reactivation in CBT patients, and subsequent secretion of IL-6, may create an increased risk for the development of HHV-6 encephalitis.
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HHV-6 encephalitis is typically defined as the presence of CNS dysfunction, a positive PCR result for HHV-6 in the CSF, and the absence of other identified causes of CNS dysfunction. 51, 52 Here we have summarized the prevalence data for all studies that have confirmed HHV-6 encephalitis via positive CSF PCR DNA test. However, this prevalence level is most likely an underestimate because some patients develop encephalitis/myelitis with positive imaging findings in the limbic area and high levels of DNA in the plasma, but are unable to undergo lumbar puncture for various clinical reasons, including severe thrombocytopenia or deteriorated general condition. 11 Ogata et al. 47 reported that, in cases where lumbar puncture is not possible, CNS dysfunction concomitant with high-level HHV-6 DNA detected in plasma via real-time PCR may be used to diagnose HHV-6 encephalitis in the absence of CSF testing. This group also found that encephalitis was only associated with plasma DNA loads of 410 4 , although CNS dysfunction was associated with low levels of plasma HHV-6 DNA. Mori et al. 11 have diagnosed HHV-6 encephalitis when such patients meet two of the following three criteria: (1) typical clinical manifestations, (2) detection of HHV-6 DNA in the peripheral blood or (3) limbic encephalopathy based on the selective involvement of the temporal lobe on magnetic resonance imaging. It must also be recognized that high levels of HHV-6 DNA can be due to ciHHV-6, and we therefore chose not to include patients without detection of HHV-6 in the CSF in our estimation. However, a separate analysis including the data from four studies of HHV-6 encephalitis where CSF testing was not possible did not alter the higher prevalence otherwise observed in UCB transplants.
Reported threshold levels of detection varied in their definition of 'HHV-6 reactivation' from 25 to 700 copies per mL in plasma and from 50 to 1000 copies per mL in whole blood among the reviewed studies. Quantitative PCR assays are not standardized and the output can vary significantly depending on factors such as the extraction method used, calibration and so on. 53, 54 A limitation of this analysis is the inability to conclusively exclude from the analysis patients with ciHHV-6 based only on reported plasma PCR values. Less than 1% (estimates range from 0.2 to 0.85%) of the population is born with ciHHV-6; these individuals will always test positive for HHV-6 in whole blood and serum, and usually will test positive in plasma and CSF-even when the virus is not actively replicating-due to natural cell breakdown in the circulation. 55 Reported prevalence data may thus be overestimated if HHV-6 DNA was detected due to ciHHV-6 rather than the result of HHV-6 reactivation. As both donors and patients may carry ciHHV-6, the combined risk of ciHHV-6 complicating the analysis is at least 1.7%, in each group.
In addition, many of the CB studies did not account for the percentage of patients who were potentially naive to HHV-6 prior to transplantation. However, the effect of this potential limitation would be expectedly rare, as this is only a concern for very young children undergoing CB transplantation. An additional limitation is the potential heterogeneity of the study populations in terms of age, demographics, conditioning regimens and post-transplant immunosuppression. To account for some of this inter-study variability, we used random effects models for our meta-analyses.
Low levels of latent HHV-6B DNA can be found in the whole blood in healthy controls, depending on the sensitivity of the assay used. A recent analysis has reported that HHV-6 is found in only 8% of whole-blood samples from healthy blood donors, with an average viral load of o100 copies per mL detected. 56 No HHV-6 DNA is found in the plasma of healthy donors, other than those with ciHHV-6. [57] [58] [59] Similarly, HHV-6 DNA is only found in the CSF in cases of active infection. The only exception would be a ciHHV-6 patient where HHV-6 DNA can be detected because of pleocytosis or contamination of the sample at the time of lumbar puncture. 55 Two multicenter studies have reported a minimum sensitivity for HHV-6 diagnostic purposes as approximately 200 copies per mL detected in plasma among both commercial and in-house assays analyzed in each study. 53, 60 Although many groups have expressed a need to implement consistent monitoring for HHV-6 in the HSCT setting, 22, 61, 62 others are hesitant to recommend such comprehensive testing as a necessity in all cases of HSCT. 63, 64 The 2009 Tomblyn consensus recommendation on preventing infections in HSCT recipients cited an absence of sufficient data to make a recommendation on monitoring or prevention of HHV-6 infection. 65 Whole-blood testing to identify patients with ciHHV-6 before undergoing CBT would help physicians interpret DNA testing and avoid unnecessary or prolonged antiviral treatment.
One study on preemptive therapy involving 29 patients suggests that even weekly plasma viral load monitoring of preemptive antiviral therapy is ineffective in preventing HHV-6-related complications after HSCT 61 because the viral load often spikes too rapidly for antiviral therapy to have any significant effect on the clinical outcome. In addition, a study with 15 CBT patients by Ishiyama et al. 66 suggested that preemptive foscarnet therapy may be effective if HHV-6 is monitored thrice weekly, suggesting the potential need for prophylactic treatment based on the dynamic of HHV-6 load in these patients.
Ishiyama et al. 66, 67 have published preliminary results of a small prospective study, suggesting the efficacy and safety of foscarnet as a prophylactic treatment in the HSCT setting. Neurological disorders occurred in 0/8 patients receiving prophylactic foscarnet compared with 4/10 control patients, including 2 with HHV-6 encephalitis. Tokimasa et al. 62 have reported significantly decreased rates of HHV-6 reactivation following HSCT in patients receiving antiviral prophylaxis with ganciclovir, but this drug has obvious disadvantages because of BM suppression, and its efficacy on HHV-6 remains uncertain. Foscarnet must be given intravenously and is associated with a risk of renal toxicity but not BM suppression. Therefore, neither of these compounds are the ideal solution for treatment or prevention of HHV-6 encephalitis in patients receiving CB transplant.
Among the new compounds in clinical development, CMX001, an agent that has a broad in vitro antiviral activity against DNA viruses including HHV-6, is the best candidate. However, prospective, controlled trials are needed to conclusively establish the efficacy of this agent. CONCLUSIONS HHV-6 reactivation and encephalitis are significant complicating factors in the post-HSCT setting, particularly in patients who have undergone HSCT with umbilical CB as the stem cell source. The best strategy to monitor and manage these patients remains to be defined. However, our meta-analysis suggests that frequent monitoring of markers of active HHV-6 infection is advisable, particularly in the setting of CBT. Future studies should be aimed at defining the benefit-risk ratio of preemptive or prophylactic antiviral intervention in specific patient groups.
